MedTrace Logo

Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)

NCT00652717 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2024-08-15

No results posted yet for this study

Summary

Collecting local data, safety and experience trial.

Conditions

  • Cardiovascular Disorder

Interventions

DRUG

Ezetimibe

Ezetimibe 10 mg daily for 42 days.

DRUG

simvastatin

simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-01
Primary Completion
2005-02-15
Completion
2005-08-04

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00652717 on ClinicalTrials.gov